Flow Cytometry
Immunophenotyping and cell population analysis reports
Meera Pillai, 32F
FC-2026-0441 · Dr. A. Sharma (Haematology) — AML immunophenotyping
Specimen: Peripheral blood + bone marrow · 23 Jun 2026, 10:00
AML — Blasts detected
| Marker | Category | % Positive | Flag | Interpretation |
|---|---|---|---|---|
| CD34 | Progenitor | 78% | High | Markedly elevated — blast cell marker |
| CD117 (c-Kit) | Progenitor | 82% | High | Myeloid blast population |
| CD13 | Myeloid | 76% | High | Myeloid differentiation |
| CD33 | Myeloid | 80% | High | Myeloid differentiation |
| HLA-DR | Myeloid | 74% | High | — |
| CD3 (T-cell) | Lymphoid | 4% | Low | Reduced — blasts crowding out T-cells |
| CD19 (B-cell) | Lymphoid | 2% | Low | — |
| MPO (Myeloperoxidase) | Myeloid | 68% | High | Confirms myeloid origin |
| CD14 | Monocytic | 5% | Normal | — |
| CD41 (Megakaryocytic) | Megakaryocytic | Not detected | Absent | No megakaryocytic differentiation |
Immunophenotyping consistent with Acute Myeloid Leukaemia (AML-M2 equivalent). Dominant blast population co-expressing CD34, CD117, CD13, CD33, HLA-DR, and MPO. Lymphoid markers absent in blast population. WHO classification: AML with myeloid differentiation. Recommend cytogenetics and FLT3/NPM1/IDH mutation testing.